in vivo News and Research

RSS

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

The need for biosimulation is primarily to do with the very high attrition rate in drug development and especially in the development of drugs for the central nervous system.

10 Dec 2013

Researchers develop new drug-eluting contact lens for prolonged delivery of glaucoma medication

10 Dec 2013

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced that positive preclinical data of selective HDAC6 inhibitor, ricolinostat (ACY-1215), in models of lymphoma were presented today in an oral presentation by Dr. Jennifer Amengual, Assistant Professor of Medicine & Experimental Therapeutics, Columbia University Medical Center.

10 Dec 2013

UC Santa Barbara professor finds method for measuring cellular forces that shape tissues, organs

Like tiny construction workers, cells sculpt embryonic tissues and organs in 3D space. This task is complicated and requires constant communication between cells to coordinate their actions and generate the forces that will shape their environment into complex tissue morphologies.

10 Dec 2013

RTMS safe and effective for hallucination in schizophrenia spectrum disorders

Repetitive transcranial magnetic stimulation uses a non-invasive and relatively painless tool to stimulate the human brain in vivo using very strong, pulsed magnetic fields. It is also used to explore and elucidate neocortical functions and treat neuropsychiatric disorders.

9 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Novartis is highlighting new research from members of the faculty at the University of Pennsylvania’s Perelman School of Medicine on the investigational chimeric antigen receptor therapy, CTL019. Several studies being presented at the American Society of Hematology annual meeting add to the scientific understanding of CTL019 in the treatment of acute lymphoblastic leukemia and chronic lymphocytic leukemia and build on earlier research findings.

9 Dec 2013

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Untreated, the mortality probably exceeds 70%. Flesh eating is a description of Toxic Inflammatory Cellulitis which usually starts by bacterial subcutaneous infection followed by freezing in phase II healing which is inflammatory.

9 Dec 2013

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge. Researchers at Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children's Hospital, and the Massachusetts Institute of Technology are one step closer to an eye drop-free reality with the development of a drug-eluting contact lens designed for prolonged delivery of latanoprost, a common drug used for the treatment of glaucoma, the leading cause of irreversible blindness worldwide.

9 Dec 2013

UC Santa Barbara extends research contract with Army Research Laboratory

UC Santa Barbara's Institute for Collaborative Biotechnologies has received an extension of its contract with the U.S. Army Research Laboratory-Army Research Office, providing an additional $48 million over three years to support research that is inspired by biological systems. The continuation in ICB funding speaks to the success of a decade of fundamental research in the areas of biotechnology, chemistry, engineering, physics, materials science, computer science, neuroscience and medicine.

9 Dec 2013

Study provides possible therapeutic strategy for Alzheimer's disease via progesterone

Steroid hormones and their metabolites within the central nervous system are commonly defined as neuroactive steroids or neurosteroids. Although neuroactive steroids have been shown to improve learning and memory ability and protect against amyloid beta peptide-induced neurotoxicity, changes in their level during Alzheimer's disease and their role in Aβ-mediated cognitive impairment remain elusive given the limitation in sample sizes and analysis methods.

8 Dec 2013

New study provides novel stem cell based, tissue engineered construct which can repair damaged bone

Researchers at the Department of Orthopaedics, of the Second Affiliated Hospital of Xi'an Jiaotong University Health Science Center, led by Dr. Kunzheng Wang and Dr. Pei Yang have developed a novel biomimetic tissue engineered bone graft based on rabbit adipose derived stem cells (rASCs), collagen I and a porous beta-tricalcium phosphate (β-TCP) scaffold.

5 Dec 2013

Blocking Cdh1 protein could accelerate development of new therapies targeting cancer

The laboratory of Marcos Malumbres, who is head of the Spanish National Cancer Research Centre's (CNIO) Cell Division & Cancer Group, working alongside Isabel Fari-as' team from the University of Valencia, shows, in a study published today in the journal Nature Communications, how in mice the elimination of the Cdh1 protein -a sub-unit of the APC/C complex, involved in the control of cell division-prevents cellular proliferation of rapidly dividing cells.

5 Dec 2013

Research findings pave new ways to treat gastrointestinal disorders

For those living with gastrointestinal disorders, such as ulcers or Crohn's disease, treatment often means quelling uncomfortable symptoms through medications or dietary changes. But what if one day treatment meant doing away with the old gut for a new gut free of inflamed or diseased tissues?

4 Dec 2013

Gladstone scientist devise new molecular sensor that can detect MS at earliest stages

For some, the disease multiple sclerosis attacks its victims slowly and progressively over a period of many years. For others, it strikes without warning in fits and starts. But all patients share one thing in common: the disease had long been present in their nervous systems, hiding under the radar from even the most sophisticated detection methods. But now, scientists at the Gladstone Institutes have devised a new molecular sensor that can detect MS at its earliest stages-even before the onset of physical signs.

3 Dec 2013

New finding links obesity and high-fat, high-sugar diets with changes in inflammatory status

Scientists have moved a step closer to an "obesity drug" that may block the effects of diets high in sugar and fats. In a new research report published in the December 2013 issue of The FASEB Journal, scientists show that there is an abnormal amount of an inflammatory protein called PAR2 in the abdominal fat tissue of overweight and obese humans and rats.

3 Dec 2013

Cyclin D1 protein controls cell cycle progression, microRNA biogenesis in breast cancer

Cyclin D1, a protein that helps push a replicating cell through the cell cycle also mediates the processing and generation of mature microRNA, according to new research publishing November 29 in Nature Communications. The research suggests that a protein strongly implicated in human cancer also governs the non-protein-coding genome. The non-coding genome, previously referred to as junk DNA, makes up most of the human genome, and unlike the coding genome, varies greatly between species.

29 Nov 2013

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Patrys Limited (ASX: PAB), a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma will be presented at the 55th American Society of Hematology Annual Meeting in New Orleans, LA on 7- 10 December 2013.

29 Nov 2013

Data from Patrys' PAT-SM6 Phase I/IIa trial in multiple myeloma to be presented at ASH Annual Meeting

Patrys Limited, a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma will be presented at the 55th American Society of Hematology Annual Meeting in New Orleans, LA on 7- 10 December 2013.

29 Nov 2013

Study uncovers mechanisms that allow stem cells to keep dividing in perpetuity

The blood stem cells that live in bone marrow are at the top of a complex family tree. Such stem cells split and divide down various pathways that ultimately produce red cells, white cells and platelets. These "daughter" cells must be produced at a rate of about one million per second to constantly replenish the body's blood supply.

27 Nov 2013

in vivo News and Research

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

Researchers develop new drug-eluting contact lens for prolonged delivery of glaucoma medication

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

UC Santa Barbara professor finds method for measuring cellular forces that shape tissues, organs

RTMS safe and effective for hallucination in schizophrenia spectrum disorders

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

‘Flesh-eating’ disease treatments: an interview with Dr. John Crew, Seton Medical Center

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

UC Santa Barbara extends research contract with Army Research Laboratory

Study provides possible therapeutic strategy for Alzheimer's disease via progesterone

New study provides novel stem cell based, tissue engineered construct which can repair damaged bone

Blocking Cdh1 protein could accelerate development of new therapies targeting cancer

Research findings pave new ways to treat gastrointestinal disorders

Gladstone scientist devise new molecular sensor that can detect MS at earliest stages

New finding links obesity and high-fat, high-sugar diets with changes in inflammatory status

Cyclin D1 protein controls cell cycle progression, microRNA biogenesis in breast cancer

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Data from Patrys' PAT-SM6 Phase I/IIa trial in multiple myeloma to be presented at ASH Annual Meeting

Study uncovers mechanisms that allow stem cells to keep dividing in perpetuity

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News